Overview
The investigators will conduct randomized and controlled clinical studies in order to preliminarily explore the efficacy and safety of low-dose cyclophosphamide and lenalidomide in maintenance therapy for MM that is not suitable for transplantation in the standard-risk group.
Description
The investigators will conduct randomized and controlled clinical studies to preliminarily explore the efficacy and safety of low-dose cyclophosphamide in maintenance therapy for MM that is not suitable for transplantation in the standard -risk group. Standard risk group MM patients who achieve VGPR or above after initial induction and consolidation therapy will use cyclophosphamide or lenalidomide as maintain therapy for 2 years.
Eligibility
Inclusion Criteria:
- After induction and consolidation therapy (8 courses of chemotherapy), MM patients in the standard-risk group who were initially unsuitable for transplantation achieved a therapeutic effect of VGPR or above;
- Secretory MM with measurable indicators;
- Age ≥ 18 years old, gender unlimited;
- No obvious dysfunction of heart, lungs, etc. (≤ Grade I);
- General KPS ≥ 70% (excluding those caused by pathological fractures and bone pain).
Exclusion Criteria:
- Cytogenetic high-risk patients;
- Recurrent or refractory MM;
- Using autologous hematopoietic stem cell transplantation as a consolidation therapy;
- The therapeutic effect did not reach VGPR or above before enrollment;
- Asymptomatic MM;
- No measurable indicators;
- KPS<50%(excluding those caused by pathological fractures）；
- Dysfunction of heart, lungs, etc. (> Grade I);
- Unable to cooperate in observing adverse reactions and therapeutic effects;
- Pregnancy, breastfeeding, or refusal of contraception by women;
- There is drug abuse and medical, psychological, or social conditions that may interfere with patients participating in research or evaluating research results;
- Any unstable or potentially endangering patient safety and compliance with the study.